Which metabolites circulate?

Drug Metabolism and Disposition

Volumn 41, Issue 5, 2013, Pages 933-951

  Loi, Cho Ming ^a   Smith, Dennis A ^a   Dalvie, Deepak ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 PYRIMIDINYLPIPERAZINE; ALCOHOL; AMINE; AMITRIPTYLINE; AZIMILIDE; BUSPIRONE; CARBOXYLIC ACID; DEETHYLAMIODARONE; DIDESETHYLAMIODARONEE; DRUG METABOLITE; ELZASONAN; IMATINIB; ITRACONAZOLE; LIPID; NORTRIPTYLINE; OLANZAPINE; OXIDE; PHENOL; PIPERAZINE; PROPAFENONE; RANITIDINE; RANOLAZINE; REPAGLINIDE; SILDENAFIL; TERFENADINE; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL; ZOLMITRIPTAN;

ACTIVE TRANSPORT; AREA UNDER THE CURVE; CHEMICAL STRUCTURE; DEALKYLATION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG ELIMINATION; DRUG METABOLISM; DRUG PENETRATION; DRUG PROTEIN BINDING; GENETIC POLYMORPHISM; LIPOPHILICITY; LIVER CELL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SYSTEMIC CIRCULATION;

EID: 84876781861     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.050278     Document Type: Review

References (76)

1. Abernethy DR, Barbey JT, Franc J, Brown KS, Feirrera I, Ford N, and Salazar DE (2001) Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation. Clin Pharmacol Ther 69:96-103.
2. Anjum S, Swan SK, Lambrecht LJ, Radwanski E, Cutler DL, Affrime MB, and Halstenson CE (1999) Pharmacokinetics of flutamide in patients with renal insufficiency. Br J Clin Pharmacol 47:43-47.
3. Baillie TA (2008) Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism. Chem Res Toxicol 21:129-137.
4. Balaz S (2009) Modeling kinetics of subcellular disposition of chemicals. Chem Rev 109: 1793-1899.
5. Borin MT, Chambers JH, Carel BJ, Gagnon S, and FreimuthWW (1997a) Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther 61:544-553.
6. Borin MT, Cox SR, Herman BD, Carel BJ, Anderson RD, and Freimuth WW (1997b) Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients. Antimicrob Agents Chemother 41:1892-1897.
7. Boyd RA, Chin SK, Don-Pedro O, Verotta D, Sheiner LB, Williams RL, and Giacomini KM (1989) The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose. Clin Pharmacol Ther 46:408-419.
8. Bratton SM, Mosher CM, Khallouki F, Finel M, Court MH, Moran JH, and Radominska-Pandya A (2012) Analysis of R-and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP- glucuronosyltransferases. J Pharmacol Exp Ther 340:46-55.
9. Budde K, Neumayer HH, Fritsche L, Sulowicz W, Stompôr T, and Eckland D (2003) The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 55:368-374.
10. Chang WH, Lin SK, Lane HY, Wei FC, Hu WH, Lam YW, and Jann MW (1998) Reversible metabolism of clozapine and clozapine N-oxide in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 22:723-739.
11. Chou C, McLachlan AJ, and Rowland M (1995) Membrane permeability and lipophilicity in the isolated perfused rat liver: 5-ethyl barbituric acid and other compounds. J Pharmacol Exp Ther 275:933-940.
12. Christ DD (1995) Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174. J Clin Pharmacol 35:515-520.
13. Dalén P, Dahl ML, Bernal Ruiz ML, Nordin J, and Bertilsson L (1998) 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 63:444-452.
14. Dalvie D, Chen W, Zhang C, Vaz AD, Smolarek TA, Cox LM, Lin J, and Obach RS (2008) Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans. Drug Metab Dispos 36:2185-2198.
15. Dalvie D, Obach RS, Kang P, Prakash C, Loi CM, Hurst S, Nedderman A, Goulet L, Smith E, and Bu HZ, et al. (2009) Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357-368.
16. DeMaio W, Kane CP, Nichols AI, and Jordan R (2011) Metabolism studies of desvenlafaxine. J Bioequiv Availab 3:151-160.
17. Davis-Bruno KL and Atrakchi A (2006) A regulatory perspective on issues and approaches in characterizing human metabolites. Chem Res Toxicol 19:1561-1563.
18. Eap CB, Buclin T, Cucchia G, Zullino D, Hustert E, Bleiber G, Golay KP, Aubert AC, Baumann P, and Telenti A, et al. (2004) Oral administration of a low dose of midazolam (75 microg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol 60:237-246.
19. Eckland DA and Danhof M (2000) Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 108 Suppl 2:S 234-S 242.
20. Freedberg KA, Innis RB, Creese I, and Snyder SH (1979) Antischizophrenic drugs: Differential plasma protein binding and therapeutic activity. Life Sci 24:2467-2473.
21. Frohna P, Lu J, Eppler S, Hamilton M, Wolf J, Rakhit A, Ling J, Kenkare-Mitra SR, and Lum BL (2006) Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects. J Clin Pharmacol 46:282-290.
22. Fura A (2006) Role of pharmacologically active metabolites in drug discovery and development. Drug Discov Today 11:133-142.
23. Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P, Hayes M, Pokorny R, Seiberling M, and Ben-Am M, et al. (2005) Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 33:1503-1512.
24. Hartman JC, Brouwer K, Mandagere A, Melvin L, and Gorczynski R (2010) Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can J Physiol Pharmacol 88:682-691.
25. Heizmann P and Ziegler WH (1981) Excretion and metabolism of 14C-midazolam in humans following oral dosing. Arzneimittelforschung 31 (12a):2220-2223.
26. Herrlin K, Yasui-Furukori N, Tybring G, Widén J, Gustafsson LL, and Bertilsson L (2003) Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol 56:415-421.
27. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, and Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: Potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176-1183.
28. Honkalammi J, Niemi M, Neuvonen PJ, and Backman JT (2011) Dose-dependent interaction between gemfibrozil and repaglinide in humans: Strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. Drug Metab Dispos 39:1977-1986.
29. Houston JB (1982) Drug metabolite kinetics. Pharmacol Ther 15:521-552.
30. Howell SR, Husbands GE, Scatina JA, and Sisenwine SF (1993) Metabolic disposition of 14Cvenlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 23:349-359.
31. Hynninen VV, Olkkola KT, Bertilsson L, Kurkinen K, Neuvonen PJ, and Laine K (2008) Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. Clin Pharmacol Ther 83:342-348.
32. Isin EM, Elmore CS, Nilsson GN, Thompson RA, and Weidolf L (2012) Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies. Chem Res Toxicol 25: 532-542.
33. Isoherranen N, Hachad H, Yeung CK, and Levy RH (2009) Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: Literature evaluation based on the metabolism and transport drug interaction database. Chem Res Toxicol 22:294-298.
34. Isoherranen N, Kunze KL, Allen KE, Nelson WL, and Thummel KE (2004) Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab Dispos 32:1121-1131.
35. Jaworski TJ, Hawes EM, McKay G, and Midha KK (1990) The metabolism of chlorpromazine Noxide in man and dog. Xenobiotica 20:107-115.
36. Kamel A, Obach RS, Colizza K, Wang W, O'Connell TN, Coelho RV, Jr, Kelley RM, and Schildknegt K (2010) Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine1b receptor antagonist elzasonan in humans. Drug Metab Dispos 38: 1984-1999.
37. Kassahun K, Mattiuz E, Nyhart E, Jr, Obermeyer B, Gillespie T, Murphy A, Goodwin RM, Tupper D, Callaghan JT, and Lemberger L (1997) Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 25:81-93.
38. Kerbusch T, Milligan PA, and Karlsson MO (2004) Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic- pharmacodynamic data. Br J Clin Pharmacol 57: 170-180.
39. Kim KA, Song WK, and Park JY (2009) Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects. Clin Pharmacol Ther 86:511-518.
40. Kirchheiner J, Schmidt H, Tzvetkov M, Keulen JT, Lötsch J, Roots I, and Brockmöller J (2007) Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 7:257-265.
41. Kroemer HK, Funck-Brentano C, Silberstein DJ, Wood AJ, Eichelbaum M, Woosley RL, and Roden DM (1989) Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation 79:1068-1076.
42. Levy RH, Lane EA, Guyot M, Brachet-Liermain A, Cenraud B, and Loiseau P (1983) Analysis of parent drug-metabolite relationship in the presence of an inducer. Application to the carbamazepine-clobazam interaction in normal man. Drug Metab Dispos 11:286-292.
43. Lin JH and Lu AY (1997) Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacol Rev 49:403-449.
44. Ling J, Johnson KA, Miao Z, Rakhit A, Pantze MP, Hamilton M, Lum BL, and Prakash C (2006) Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab Dispos 34: 420-426.
45. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, and Bjornsson TD (1995) Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 58:641-649.
46. Lutz JD, Fujioka Y, and Isoherranen N (2010) Rationalization and prediction of in vivo metabolite exposures: The role of metabolite kinetics, clearance predictions and in vitro parameters. Expert Opin Drug Metab Toxicol 6:1095-1109.
47. Lutz JD and Isoherranen N (2012) Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: Dextromethorphan and omeprazole. Drug Metab Dispos 40:159-168.
48. Mahmood I and Sahajwalla C (1999) Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet 36:277-287.
49. Matsushima S, Maeda K, Hayashi H, Debori Y, Schinkel AH, Schuetz JD, Kusuhara H, and Sugiyama Y (2008) Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. Mol Pharmacol 73:1474-1483.
50. McDonald MG, Au NT, Wittkowsky AK, and Rettie AE (2012) Warfarin-amiodarone drug-drug interactions: Determination of [I](u)/K(I,u) for amiodarone and its plasma metabolites. Clin Pharmacol Ther 91:709-717.
51. Morse GD, Fischl MA, Shelton MJ, Cox SR, Driver M, DeRemer M, and Freimuth WW (1997) Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 41:169-174.
52. Nedderman AN, Dear GJ, North S, Obach RS, and Higton D (2011) From definition to implementation: A cross-industry perspective of past, current and future MIST strategies. Xenobiotica 41:605-622.
53. Obach RS, Lombardo F, and Waters NJ (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36: 1385-1405.
54. Oppermann UC and Maser E (2000) Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions. Toxicology 144:71-81.
55. Påhlman I and Gozzi P (1999) Serum protein binding of tolterodine and its major metabolites in humans and several animal species. Biopharm Drug Dispos 20:91-99.
56. Patat A, Troy S, Burke J, Trocherie S, Danjou P, Le Coz F, Allain H, and Gandon JM (1998) Absolute bioavailability and electroencephalographic effects of conventional and extendedrelease formulations of venlafaxine in healthy subjects. J Clin Pharmacol 38:256-267.
57. Penner N, Xu L, and Prakash C (2012) Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: Why, when, and how? Chem Res Toxicol 25:513-531.
58. Riley P, Figary PC, Entwisle JR, Roe AL, Thompson GA, Ohashi R, Ohashi N, and Moorehead TJ (2005) The metabolic profile of azimilide in man: In vivo and in vitro evaluations. J Pharm Sci 94:2084-2095.
59. Rochester CL, Gammon DE, Shane E, and Bilezikian JP (1980) A radioreceptor assay for propranolol and 4-hydroxypropranolol. Clin Pharmacol Ther 28:32-39.
60. Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, Smith DA, Walker DK, and Wood N (2003) The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 31:731-741.
61. Roffey SJ, Obach RS, Gedge JI, and Smith DA (2007) What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 39:17-43.
62. Sarapa N, Britto MR, Mainka MB, and Parivar K (2005) The effect of mild and moderate hepatic impairment on the pharmacokinetics of valdecoxib, a selective COX-2 inhibitor. Eur J Clin Pharmacol 61:247-256.
63. Sauer JM, Ponsler GD, Mattiuz EL, Long AJ, Witcher JW, Thomasson HR, and Desante KA (2003) Disposition and metabolic fate of atomoxetine hydrochloride: The role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos 31:98-107.
64. Sauer JM, Ring BJ, and Witcher JW (2005) Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 44:571-590.
65. Schaber G, Stevens I, Gaertner HJ, Dietz K, and Breyer-Pfaff U (1998) Pharmacokinetics of clozapine and its metabolites in psychiatric patients: Plasma protein binding and renal clearance. Br J Clin Pharmacol 46:453-459.
66. Smith DA and Dalvie D (2012) Why do metabolites circulate? Xenobiotica 42:107-126.
67. van Giersbergen PL, Halabi A, and Dingemanse J (2002) Single-and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole. Br J Clin Pharmacol 53: 589-595.
68. van Heiningen PN, Hatorp V, Kramer Nielsen K, Hansen KT, van Lier JJ, De Merbel NC, Oosterhuis B, and Jonkman JH (1999) Absorption, metabolism and excretion of a single oral dose of (14)C-repaglinide during repaglinide multiple dosing. Eur J Clin Pharmacol 55: 521-525.
69. von Moltke LL, Greenblatt DJ, Granda BW, Grassi JM, Schmider J, Harmatz JS, and Shader RI (1999) Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: Cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl) 145: 113-122.
70. Voorman RL, Maio SM, Hauer MJ, Sanders PE, Payne NA, and Ackland MJ (1998a) Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: Probable involvement of CYP2D6 and CYP3A. Drug Metab Dispos 26:631-639.
71. Voorman RL, Maio SM, Payne NA, Zhao Z, Koeplinger KA, and Wang X (1998b) Microsomal metabolism of delavirdine: Evidence for mechanism-based inactivation of human cytochrome P450 3A. J Pharmacol Exp Ther 287:381-388.
72. Weber C, Gasser R, and Hopfgartner G (1999) Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab Dispos 27: 810-815.
73. Weiss YA, Safar ME, Lehner JP, Levenson JA, Simon A, and Alexandre JM (1978) (+)-Propranolol clearance, an estimation of hepatic blood flow in man. Br J Clin Pharmacol 5: 457-460.
74. Yeung CK, Fujioka Y, Hachad H, Levy RH, and Isoherranen N (2011) Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency. Clin Pharmacol Ther 89:105-113.
75. Yeung PK, Hubbard JW, Korchinski ED, and Midha KK (1993) Pharmacokinetics of chlorpromazine and key metabolites. Eur J Clin Pharmacol 45:563-569.
76. Yuan JJ, Yang DC, Zhang JY, Bible R, Jr, Karim A, and Findlay JW (2002) Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. Drug Metab Dispos 30: 1013-1021.